Arcus Biosciences (RCUS) Competitors

Arcus Biosciences (NYSE:RCUS) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Which has higher valuation and earnings, RCUS or CYTK?

Arcus Biosciences has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$263M	5.55	-$307M	-$3.15	-5.07
Cytokinetics	$3.22M	1,794.59	-$526.24M	-$5.38	-9.10

Which has more risk and volatility, RCUS or CYTK?

Arcus Biosciences has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Does the MarketBeat Community believe in RCUS or CYTK?

Cytokinetics received 613 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 79.74% of users gave Cytokinetics an outperform vote while only 65.54% of users gave Arcus Biosciences an outperform vote.

Company	Underperform	Outperform
Arcus Biosciences	Outperform Votes 194 65.54%	Underperform Votes 102 34.46%
Cytokinetics	Outperform Votes 807 79.74%	Underperform Votes 205 20.26%

Do analysts rate RCUS or CYTK?

Arcus Biosciences currently has a consensus target price of $34.00, suggesting a potential upside of 113.03%. Cytokinetics has a consensus target price of $84.07, suggesting a potential upside of 71.74%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcus Biosciences is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cytokinetics	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media refer more to RCUS or CYTK?

In the previous week, Cytokinetics had 11 more articles in the media than Arcus Biosciences. MarketBeat recorded 16 mentions for Cytokinetics and 5 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.78 beat Cytokinetics' score of 0.78 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in RCUS or CYTK?

92.9% of Arcus Biosciences shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by insiders. Comparatively, 3.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is RCUS or CYTK more profitable?

Arcus Biosciences has a net margin of -102.66% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-102.66%	-45.59%	-22.38%
Cytokinetics	-17,906.25%	N/A	-50.21%

Summary

Arcus Biosciences beats Cytokinetics on 13 of the 19 factors compared between the two stocks.